openPR Logo
Press release

Biologics and Biosimilars Market to 2027 | Pfizer, Intas Pharmaceuticals, Biocon, Dr. Reddy's Laboratories, Sandoz International GmbH (Novartis division), CELLTRION, Amgen, STADA Arzneimittel AG, Apotex, Biogen

03-25-2020 12:49 PM CET | Health & Medicine

Press release from: Premium Market Insights

Biologics and Biosimilars Market to 2027 - Global Analysis and Forecast

Biologics and Biosimilars Market to 2027 - Global Analysis and Forecast

Biosimilars are similar to reference drugs. However, they exhibit a minor difference in clinically inactive components. They are identical in terms of safety, effectiveness, and clinical significance as their reference product. Biologics are produced from living organisms by using complex manufacturing processes. A wide variety of biologics are available such as monoclonal antibodies, therapeutic proteins, vaccines, and others. These are active substances obtained from living cells of plants or animals. Biosimilars are approximately 20-25% cheaper than their reference/branded products. Moreover, biologics are used in the treatment of a wide variety of indications such as osteoporosis, arthritis, cystic fibrosis, autoimmune disorders, and cancer. For instance, some of the approved biosimilars are Mvasi (Avastin), Erelzi (Enbrel), Ogivri (Herceptin), Amjevita (Amjevita), among others.

In the last two decades, the biotechnology industry developed a wide range of biologic drugs, changing the medicine landscape worldwide. Biologics are being successfully being used to treat many chronic diseases. The increasing availability of biosimilars is contributing to the growth of the market. For instance, Biogen, which is a prominent manufacturer of biosimilar therapies, offers an anti-TNF therapies portfolio. These are used for the treatment of various inflammatory conditions like rheumatoid arthritis, bowel disease, psoriatic arthritis, among others. Biosimilars are helping in expanding cost-effective treatment options for chronic diseases. Increasing cases of life-threatening diseases are growing demand for such therapies. Additionally, emerging markets such as China, India, are broadening the scope of the market and presenting growth opportunities for future growth.

Top Companies Covered in this Report:
1. Pfizer Inc., 2. Intas Pharmaceuticals Ltd., 3. Biocon, 4. Dr. Reddy's Laboratories Ltd., 5. Sandoz International GmbH (Novartis division), 6. CELLTRION INC., 7. Amgen Inc., 8. STADA Arzneimittel AG, 9. Apotex Inc., 10. Biogen

Get sample copy of "Biologics and Biosimilars Market" at: https://www.premiummarketinsights.com/sample/TIP00024684

What is the Market Scope?

The "Global Biologics and Biosimilars Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of 3D Printed Medical Implant with detailed market segmentation by Component, Implantation Technology, Application, End User and geography. The global BIOLOGICS AND BIOSIMILARS are expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading BIOLOGICS AND BIOSIMILARS Market players and offers key trends and opportunities in the market.

What is the Market Segmentation?

The global biologics and biosimilars market is segmented on the basis of product and application. Based on product, the market is segmented as recombinant glycosylated proteins, recombinant non-glycosylated proteins and recombinant peptides. Recombinant glycosylated proteins are further sub segmented into monoclonal antibodies, erythroprotein, and others. Recombinant non-glycosylated proteins are further sub divided into insulin, Granulocyte Colony-stimulating Factor, and interferon. Based on indication, the market is segmented as chronic diseases, oncology, autoimmune diseases, infectious diseases, blood disorders, growth hormone deficiency and other.

What is the Regional Framework?

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Biologics and Biosimilars market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Biologics and Biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

Have any query? Enquire about report at: https://www.premiummarketinsights.com/discount/TIP00024684

Fundamentals of Table of Content:

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Biologics and Biosimilars Market Size
2.2 Biologics and Biosimilars Growth Trends by Regions
2.3 Industry Trends

3 Market Share by Key Players
3.1 Biologics and Biosimilars Market Size by Manufacturers
3.2 Biologics and Biosimilars Key Players Head office and Area Served
3.3 Key Players Biologics and Biosimilars Product/Solution/Service
3.4 Date of Enter into Biologics and Biosimilars Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Biologics and Biosimilars Sales by Product
4.2 Global Biologics and Biosimilars Revenue by Product
4.3 Biologics and Biosimilars Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Biologics and Biosimilars Breakdown Data by End User

Buy this Report Now at: https://www.premiummarketinsights.com/buy/TIP00024684

Contact Us:
Call: +912067274191
Email: sales@premiummarketinsights.com

About Premiummarketinsights:

Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biologics and Biosimilars Market to 2027 | Pfizer, Intas Pharmaceuticals, Biocon, Dr. Reddy's Laboratories, Sandoz International GmbH (Novartis division), CELLTRION, Amgen, STADA Arzneimittel AG, Apotex, Biogen here

News-ID: 1983761 • Views: 86

More Releases from Premium Market Insights

Blockchain Supply Chain Market projected to reach $ 9,852.91 million and growing …
The research dives deep into the global share, size, and trends, as well as growth rate of the Blockchain Supply Chain market to project its progress during the forecast period. Most importantly, the report further identifies the past, present,and future trends that are expected to influence the development rate of the Blockchain Supply Chain market. The research segments the marketon the basis of product type, application, and region. Blockchain Supply Chain
Blockchain In Insurance Market to reach USD 4315.1 million and grow with a healt …
Premium Market Insights delivers well-researched industry-wide information on the Blockchain In Insurance market. It studies the market's essential aspects such as top participants, expansion strategies, business models, and other market features to gain improved market insights. Additionally, it focuses on the latest advancements in the sector and technological development, executive tools, and tactics that can enhance the performance of the sectors. Blockchain In Insurance Market to reach USD 4315.1 million and
Current Status and Future Prospects in Biopesticides Market 2022 with top key pl …
Biopesticides are essentially microbial toxins that can be defined as a biological poison derived from a microorganism, such as a bacterium or fungus. Pathogenesis by microbial entomopathogens occurs by invasion of pathogen through the gut of the insect followed by its multiplication, resulting to death of the insect. Request for sample report@: https://bit.ly/3bMBkEC Top Companies Covered in this Report: Actagro LLC.,Ag Biochem Inc.,Agbitech Pty Ltd.,Bio-Tech Ltd.,Amit Biotech,Amvac Chemical,Andermatt Biocontrol AG,Arbico Organics,Bayer,BASF Corp. The
Rise of the Packaging Robots Market 2023 major key companies profiled like ABB L …
Robots in packaging processes are designed to reduce the manual workforce and increase the production throughput. Robotics provide flexibility and accuracy in applications such as cartooning, filling, tray packing, and de-palletizing. In addition, companies are benefited with robotic palletizing when they start losing productivity due to manual palletizing. Request for sample report@: https://bit.ly/345v8ER Top Companies Covered in this Report:, ABB Limited, Krones AG, Fanuc Corporation, Schneider Electric SE, Yaskawa America Inc., Mitsubishi

All 5 Releases


More Releases for Biosimilars

PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on